rss
Evid Based Nurs 11:11 doi:10.1136/ebn.11.1.11
  • Treatment

Review: vaccines against human papillomavirus prevent cervical cancer precursors in young women

Vaccines against oncogenic types of human papillomavirus (HPV) v placebo or no HPV vaccine to prevent vaccine-type HPV-associated cervical cancer precursors in young women (modified intention-to-treat population)*
Outcomes at 15–60 months Number of trials (n) Weighted event rates RRR (95% CI) NNT (CI)
Vaccine Control
Grade 2 CIN or worse 5 (36 266) 0.8% 1.5% 48% (37 to 57) 138 (116 to 179)
Any grade CIN 5 (24 613) 0.7% 1.9% 64% (55 to 71) 81 (73 to 95)
Persistent HPV infection at 6 months 3 (14 207) 0.9% 4.0% 77% (72 to 81) 33 (31 to 35)
Persistent HPV infection at 12 months 2 (7774) 0.4% 1.6% 74% (59 to 84) 86 (76 to 108)
External genital lesions 2 (5981) 1.1% 3.5% 69% (56 to 77) 41 (37 to 51)
Serious adverse events 6 (39 609) 2.2% 2.2% 0% (−14 to 13) Not significant
  • *CIN  =  cervical intraepithelial neoplasia; other abbreviations defined in glossary. Weighted event rates, RRR, NNT, and CI calculated from data in article.

This Article

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article